Evidence map›Paper›PMID 36866253›Full record

ReviewNanoscale advances2023

Recent trends in emerging strategies for ferroptosis-based cancer therapy.

Hongli Yu, Jianqin Yan, Zhipeng Li, Limian Yang, Fang Ju, Yong Sun

Open access · goldAbstract readReview
In one paragraph

Review in Nanoscale advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. The role of metals in cancer and the use of metal chelators as a potential treatment strategy.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Ferroptosis and its current progress in gastric cancer.Frontiers in cell and developmental biology · 2024
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hongli YuDepartment of Pharmaceutics, School of Pharmacy, Qingdao University Qingdao 266073 China sunyong@qdu.edu.cn.
Jianqin YanDepartment of Pharmaceutics, School of Pharmacy, Qingdao University Qingdao 266073 China sunyong@qdu.edu.cn.ORCID https://orcid.org/0000-0003-3218-0264
Zhipeng LiDepartment of Pharmaceutics, School of Pharmacy, Qingdao University Qingdao 266073 China sunyong@qdu.edu.cn.ORCID https://orcid.org/0000-0001-8154-6221
Limian YangQingdao Mingde School Qingdao 266000 China.
Fang JuDepartment of Oncology, The Second Affiliated Hospital of Qingdao University Qingdao 266000 China jufangjufang@sina.com.
Yong SunDepartment of Pharmaceutics, School of Pharmacy, Qingdao University Qingdao 266073 China sunyong@qdu.edu.cn.ORCID https://orcid.org/0000-0003-0365-1151
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis, an iron-dependent mode of regulated cell death, is induced by lipid peroxidation, whose occurrence and execution are primarily controlled by metabolism of iron, lipids, amino acids and glutathione. In recent years, the fast-growing studies of ferroptosis in cancer have promoted its application in cancer therapy. So, this review focuses on the feasibility and characteristics of initiating ferroptosis for cancer therapy, as well as the main mechanism of ferroptosis. And various emerging strategies of cancer therapy based on ferroptosis are then highlighted to describe their design, mechanism of action, and anticancer applications. In addition ferroptosis in diverse cancer types is summarized, some considerations for the research of various preparations that can cause ferroptosis are introduced, and this emerging field is discussed in terms of its challenges and future development directions.

Identifiers

PMID36866253
PMCPMC9972547
OpenAlexW4320736957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.